BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

312 related articles for article (PubMed ID: 35628381)

  • 61. Waldenstrom Macroglobulinemia: Familial Predisposition and the Role of Genomics in Prognosis and Treatment Selection.
    Kapoor P; Paludo J; Ansell SM
    Curr Treat Options Oncol; 2016 Mar; 17(3):16. PubMed ID: 26942591
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Detection of the MYD88
    Wu YY; Jia MN; Cai H; Qiu Y; Zhou DB; Li J; Cao XX
    Ann Hematol; 2020 Aug; 99(8):1763-1769. PubMed ID: 32577844
    [TBL] [Abstract][Full Text] [Related]  

  • 63. MYD88 L265P and CXCR4 mutations in lymphoplasmacytic lymphoma identify cases with high disease activity.
    Schmidt J; Federmann B; Schindler N; Steinhilber J; Bonzheim I; Fend F; Quintanilla-Martinez L
    Br J Haematol; 2015 Jun; 169(6):795-803. PubMed ID: 25819228
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Cutaneous Involvement in Waldenström's Macroglobulinaemia.
    Stien S; Durot E; Durlach A; Beylot-Barry M; Adamski H; Beltraminelli H; Bohelay G; Carlotti A; Carpentier O; Cornillet P; Dubois R; Franck N; Husson B; Laroche L; Maubec E; le Clech C; Machet L; Ortonne N; Ram-Wolff C; Vergier B; Grange F
    Acta Derm Venereol; 2020 Aug; 100(15):adv00225. PubMed ID: 32488284
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Molecular and genetic biomarkers implemented from next-generation sequencing provide treatment insights in clinical practice for Waldenström macroglobulinemia.
    Wang Y; Gali VL; Xu-Monette ZY; Sano D; Thomas SK; Weber DM; Zhu F; Fang X; Deng M; Zhang M; Hagemeister FB; Li Y; Orlowski RZ; Lee HC; Young KH
    Neoplasia; 2021 Apr; 23(4):361-374. PubMed ID: 33735664
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Extracellular vesicle-mediated transfer of constitutively active MyD88
    Manček-Keber M; Lainšček D; Benčina M; Chen JG; Romih R; Hunter ZR; Treon SP; Jerala R
    Blood; 2018 Apr; 131(15):1720-1729. PubMed ID: 29358175
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Insights into the genomic landscape of MYD88 wild-type Waldenström macroglobulinemia.
    Hunter ZR; Xu L; Tsakmaklis N; Demos MG; Kofides A; Jimenez C; Chan GG; Chen J; Liu X; Munshi M; Gustine J; Meid K; Patterson CJ; Yang G; Dubeau T; Samur MK; Castillo JJ; Anderson KC; Munshi NC; Treon SP
    Blood Adv; 2018 Nov; 2(21):2937-2946. PubMed ID: 30401751
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Molecular characterization of heavy chain immunoglobulin gene rearrangements in Waldenström's macroglobulinemia and IgM monoclonal gammopathy of undetermined significance.
    Martín-Jiménez P; García-Sanz R; Balanzategui A; Alcoceba M; Ocio E; Sanchez ML; González M; San Miguel J
    Haematologica; 2007 May; 92(5):635-42. PubMed ID: 17488687
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Characteristics of Waldenström Macroglobulinemia in Korean Patients According to Mutational Status of MYD88 and CXCR4: Analysis Using Ultra-Deep Sequencing.
    Shin DW; Kim SM; Kim JA; Park HS; Hwang SM; Im K; Kim S; Kim J; Kwon S; Yoon SS; Lee DS
    Clin Lymphoma Myeloma Leuk; 2019 Aug; 19(8):e496-e505. PubMed ID: 31221512
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Clinical application of genomics in Waldenström macroglobulinemia.
    Branagan AR; Lei M; Treon SP; Castillo JJ
    Leuk Lymphoma; 2021 Aug; 62(8):1805-1815. PubMed ID: 33569985
    [TBL] [Abstract][Full Text] [Related]  

  • 71. CXCR4 mutations affect presentation and outcomes in patients with Waldenström macroglobulinemia: A systematic review.
    Castillo JJ; Moreno DF; Arbelaez MI; Hunter ZR; Treon SP
    Expert Rev Hematol; 2019 Oct; 12(10):873-881. PubMed ID: 31343930
    [No Abstract]   [Full Text] [Related]  

  • 72. Diagnostic value of bone marrow core biopsy patterns in lymphoplasmacytic lymphoma/Waldenström macroglobulinaemia and description of its mutational profiles by targeted NGS.
    Garcia-Reyero J; Martinez Magunacelaya N; Gonzalez de Villambrosia S; Gomez Mediavilla A; Urquieta Lam M; Insunza A; Tonda R; Beltran S; Gut M; Gonzalez A; Montes-Moreno S
    J Clin Pathol; 2020 Sep; 73(9):571-577. PubMed ID: 31980558
    [TBL] [Abstract][Full Text] [Related]  

  • 73. SOHO State of the Art Updates and Next Questions: Waldenström Macroglobulinemia - 2021 Update on Management and Future Directions.
    Thomas SK
    Clin Lymphoma Myeloma Leuk; 2022 Jun; 22(6):347-355. PubMed ID: 34980578
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Clinical and molecular characteristics of lymphoplasmacytic lymphoma not associated with an IgM monoclonal protein: A multicentric study of the Rete Ematologica Lombarda (REL) network.
    Varettoni M; Boveri E; Zibellini S; Tedeschi A; Candido C; Ferretti VV; Rizzo E; Doni E; Merli M; Farina L; Goldaniga M; Gallì A; Rattotti S; Frustaci AM; Deodato M; Bandiera L; Isimbaldi G; Uccella S; Cabras AD; Gianelli U; Baldini L; Paulli M; Arcaini L
    Am J Hematol; 2019 Nov; 94(11):1193-1199. PubMed ID: 31378966
    [TBL] [Abstract][Full Text] [Related]  

  • 75. The MYD88
    Kapoor P
    Br J Haematol; 2019 Nov; 187(4):413-415. PubMed ID: 31298748
    [No Abstract]   [Full Text] [Related]  

  • 76. Clinical Implications of Genomic Profile in Waldenström Macroglobulinemia.
    Moreno DF; Fernández de Larrea C
    Hematol Oncol Clin North Am; 2023 Aug; 37(4):659-670. PubMed ID: 37211494
    [TBL] [Abstract][Full Text] [Related]  

  • 77. MYD88 wild-type Waldenstrom Macroglobulinaemia: differential diagnosis, risk of histological transformation, and overall survival.
    Treon SP; Gustine J; Xu L; Manning RJ; Tsakmaklis N; Demos M; Meid K; Guerrera ML; Munshi M; Chan G; Chen J; Kofides A; Patterson CJ; Yang G; Liu X; Severns P; Dubeau T; Hunter ZR; Castillo JJ
    Br J Haematol; 2018 Feb; 180(3):374-380. PubMed ID: 29181840
    [TBL] [Abstract][Full Text] [Related]  

  • 78.
    Poulain S; Roumier C; Bertrand E; Renneville A; Caillault-Venet A; Doye E; Geffroy S; Sebda S; Nibourel O; Nudel M; Herbaux C; Renaud L; Tomowiak C; Guidez S; Tricot S; Roche-Lestienne C; Quesnel B; Preudhomme C; Leleu X
    Clin Cancer Res; 2017 Oct; 23(20):6325-6335. PubMed ID: 28754818
    [No Abstract]   [Full Text] [Related]  

  • 79. [Evaluation of clinical characteristics, MYD88(L265P) mutation, CXCR4(WHIM) mutation and prognosis in Waldenström macroglobulinemia: A single center retrospective study of 93 patients].
    Cao XX; Meng Q; Cai H; Mao YY; Duan MH; Zhu TN; Zhang W; Han B; Zhuang JL; Cai HC; Chen M; Feng J; Han X; Zhang Y; Yang C; Zhang L; Zhou DB; Li J
    Zhonghua Xue Ye Xue Za Zhi; 2017 Jun; 38(6):494-498. PubMed ID: 28655092
    [No Abstract]   [Full Text] [Related]  

  • 80. Role of MYD88 in lymphoplasmacytic lymphoma diagnosis and pathogenesis.
    Rossi D
    Hematology Am Soc Hematol Educ Program; 2014 Dec; 2014(1):113-8. PubMed ID: 25696843
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.